Adam Lambert, Ph.D.

Director, Pre-formulation and Analytical Chemistry

Adam Lambert has a Ph.D. in Chemistry from the University of Akron in Akron Ohio and more than 12- years of pharmaceutical industry experience in analytical, formulation and process development of novel and technically challenging pharmaceutical products.

Dr. Lambert has developed a wide range of analytical methods and pharmaceutical formulations for both large and small molecule drug products, including monoclonal antibodies.

Prior to joining CoreRx, Dr. Lambert was the Principal Analytical Chemist at Oakwood Laboratories, where he was responsible for validation of all analytical methods, and preparation of CTDs for NDA submissions. Prior to Oakwood he worked as a Research Scientist for Baxter, Manager of Formulation at Iomai Corporation (Now Intercell, USA), and Senior Scientist at AAI. Through these positions, Dr. Lamberts key accomplishments include the development of ProMaxx® microsphere technology (pulmonary delivery of proteins and stabilization of monoclonal antibodies), and the first human trials of a manufactured vaccine patch (E coli vaccine). Dr. Lambert has considerable experience in the research, development, and analysis of pharmaceutical products from pre-clinical phases through NDA submission.